55 results about "Ischemic cardiomyopathy" patented technology

Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and / or applying to the patient a therapeutically effective amount of stem cells and / or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.

The invention belongs to the Chinese medicine pharmaceutical field and relates to the application of specific monomer leonurine in Chinese medicinal herb motherwort in preparing medicine combination, in particular to the application in preparing the medicine combination which cures ischemic cardiomyopathy. By the experimental research of anoxic myocardium models in vitro, the result shows that the leonurine can increase livability of ischemic myocyte, can decrease the leakage rate of lactate dehydrogenase, can increase the activity of antioxidase catalase, can increase the activity of SOD, can minish the level of lipid peroxidation products, and proves that the leonurine has obvious protective effect on ischemic myocardium and prepares the medicine which cures ischemic cardiomyopathy.

The invention discloses medical application of berberine. The berberine has prominent functions of resisting noradrenaline and stimulating pulmonary arterial smooth muscle cells and is capable of effectively improving the function of a right ventricular, and meanwhile, the berberine is capable of remarkably reducing mean pulmonary arterial pressure; the functions of preventing in-stent restenosis and stent thrombosis are obtained; the berberine has a unique function of preventing and treating myocardial infarction; the berberine is capable of effectively preventing and treating ischemic cardiomyopathy and cardiac failure caused thereby.

The invention discloses a medicine composition for ischemic diseases, which comprises the following raw materials by weight portion: 5 to 15 portions of radix astragali, 2 to 8 portions of Salvia miltiorrhiza, 1 to 5 portions of ligusticum wallichii, 1 to 5 portions of safflower and 1 to 3 portions of earthworms. The invention simultaneously discloses application of the medicine composition in preparing pharmaceutical preparation for treating ischemic cerebrovascular disorder, application of the medicine composition in pharmaceutical preparation for treating ischemic cardiomyopathy, and application of the medicine composition in pharmaceutical preparation for treating ischemic enteropathy. The medicine composition can be used for preventing and treating ischemic diseases such as ischemic cerebrovascular disorder, ischemic cardiomyopathy and ischemic enteropathy, and can also be used for treating coronary heart disease, arteriosclerosis and mesenteric vein embolism. The medicine composition has strong pertinence and obvious medicine effect, and provides more application selections for clinical medication.

The invention discloses a capsule type coronary oppressing device and a method for manufacturing a chronic myocardial ischemia animal model. The capsule type coronary oppressing device at least comprises a capsule body and an injection pipe communicated with the capsule body. The method for manufacturing a chronic myocardial ischemia animal model includes the steps that firstly, an animal sample is fixed on an experiment table; secondly, a skin is shaved; thirdly, the thoracic cavity is cut open and the heart is exposed; fourthly, the coronary artery is extracted, the capsule body of the capsule type coronary oppressing device is fixed on the myocardium and bundled with the coronary artery, and at least a rubber tube section of the injection pipe of the capsule type coronary oppressing device is fixed below the skin of the animal sample; fifthly, the thorax is closed for feeding. According to the capsule type coronary oppressing device and the method for manufacturing the chronic myocardial ischemia animal model, the chronic myocardial ischemia animal model which can perform multiple times of intermittent ischemia reperfusion on the cardiac muscle and can be continuously studied can be constructed. New ideas and a basis can be provided for treating the ischemic cardiomyopathy in clinic work, and new progresses can be provided for treatment theories of the ischemic cardiomyopathy.